stockrow
Saturday 7 November 2026
Export AFMDQ’s income statement to Excel — free account
Affimed N.V.
AFMDQ Healthcare Biotechnology
Affimed N.V.’s revenue for fiscal 2023 (year ended December 2023) was $9.0 million, down 79.4% from fiscal 2022.
0.00
0.00
NaN
Follow AFMDQ
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM Sep ’24 | Trend | 10 yrs | 2024e | 2025e | 2026e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | 7 | 2 | 28 | 24 | 32 | 48 | 44 | 9 | 1 | +3.6% | 1 | 1 | 1 | (49.9%) | |
| Gross margin, % | — | — | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 0.0 pt | ||||||
| EBT | — | — | (36) | (34) | (23) | (36) | (47) | (68) | (91) | (115) | (76) | +18.1% | ||||||
| EBT margin, % | — | — | (511.15) | (1,504.63) | (82.06) | (151.28) | (145.86) | (142.50) | (207.97) | (1,280.19) | (7,834.14) | (769.0) pt | ||||||
| Net income | — | — | (36) | (34) | (23) | (36) | (47) | (68) | (91) | (115) | (76) | +18.2% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 2.10 | 0.52 | 4.63 | 3.73 | 3.88 | 4.00 | 3.06 | 0.60 | 0.06 | (16.4%) | |||||
| Earnings | — | — | (10.60) | (7.80) | (3.80) | (5.60) | (5.70) | (5.70) | (6.30) | (7.67) | (4.95) | (4.5%) | ||||||
| Cash flow | — | — | (10.69) | (6.60) | 9.65 | (5.07) | (2.65) | (8.57) | (7.76) | (7.99) | (5.19) | (4.1%) | ||||||
| Capex | — | — | (0.09) | (0.16) | (0.14) | (0.26) | (0.06) | (0.38) | (0.05) | (0.27) | 0.02 | +17.7% | ||||||
| Free cash flow | — | — | (10.78) | (6.76) | 9.51 | (5.32) | (2.72) | (8.95) | (7.81) | (8.26) | (5.18) | (3.7%) | ||||||
| Book value | — | — | 12.89 | 8.16 | 7.83 | 6.74 | 9.85 | 13.46 | 11.32 | 4.19 | 1.17 | (14.8%) | ||||||
| Shares, m | — | — | 3 | 4 | 6 | 6 | 8 | 12 | 14 | 15 | 15 | +23.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | 10.00 | 26.48 | 6.71 | 7.35 | 15.00 | 13.81 | 3.95 | 10.43 | 0.00 | 11.7 | ||||||
| P/B | — | — | 1.63 | 1.69 | 3.97 | 4.06 | 5.91 | 4.10 | 1.07 | 1.49 | 0.00 | 3.0 | ||||||
| EV/Sales | — | — | 3.61 | 10.22 | 2.33 | 2.59 | 9.83 | 9.35 | (0.22) | 3.09 | (19.16) | 5.1 | ||||||
| EV/FCF | — | — | (0.70) | (0.78) | 1.14 | (1.81) | (14.05) | (4.17) | 0.09 | (0.22) | 0.22 | (2.6) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (36) | (29) | 58 | (33) | (22) | (102) | (111) | (119) | (84) | +18.9% | |||||
| Capex | — | — | 0 | (1) | (1) | (2) | (1) | (5) | (1) | (4) | 0 | +45.9% | ||||||
| Free cash flow | — | — | (36) | (30) | 58 | (34) | (23) | (107) | (111) | (123) | (83) | +19.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 46 | 39 | 87 | 79 | 96 | 168 | 170 | 63 | 17 | +4.6% | |||||
| Net debt | — | — | (45) | (37) | (123) | (114) | (167) | (213) | (182) | (66) | (19) | +5.7% | ||||||
| Shareholders’ equity | — | — | 43 | 36 | 47 | 43 | 82 | 161 | 161 | 63 | 19 | +5.5% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (50.21) | (66.52) | (24.74) | (27.56) | (28.94) | (29.14) | (37.94) | (72.47) | (86.68) | (22.3) pt | |||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (13,558.83) | 0.0 pt | ||||||
| ROE | — | — | (60.64) | (86.95) | (55.37) | (79.93) | (75.28) | (55.99) | (56.29) | (102.52) | (148.64) | (41.9) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | 53 | 61 | 69 | 137 | 163 | 197 | 228 | 78 | — | +5.7% | |||||
| Revenue/emp, $m | — | — | 0.13 | 0.04 | 0.41 | 0.17 | 0.20 | 0.24 | 0.19 | 0.11 | — | (2.0%) | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2023 · latest quarter Sep 2024
Affimed N.V. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ERNA Ernexa Therapeutics Inc. | $3.0M | — (loss-making) | — (loss-making) | −94.12% (below 0%: shrinking) | n/m | −64.10% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CMND Clearmind Medicine Inc. | $3.0M | — (loss-making) | — | — | n/m | −77.94% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| KALA KALA BIO, Inc. | $3.0M | — (loss-making) | — (loss-making) | −86.31% (below 0%: shrinking) | n/m | +80.19% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BCAB BioAtla, Inc. | $2.9M | — (loss-making) | — (loss-making) | +4,233.33% (above 0%: growing) | n/m | +97.03% (above 0%: growing) | 100.00% | 3.49% | Compare |
| JUNS Jupiter Neurosciences, Inc. | $2.8M | — (loss-making) | — | — | n/m | −177.06% (below 0%: shrinking) | 87.19% | (11,334.30%) | Compare |
| AFMDQ Affimed N.V. | $2.8M | — (loss-making) | — (loss-making) | −92.02% (below 0%: shrinking) | n/m | +46.95% (above 0%: growing) | 100.00% | (9,216.90%) | |
| DCOY Decoy Therapeutics Inc | $2.7M | — (loss-making) | — (loss-making) | −84.61% (below 0%: shrinking) | n/m | −212.47% (below 0%: shrinking) | 100.00% | (1,055.98%) | Compare |
| NRSN NeuroSense Therapeutics Ltd. | $2.6M | — (loss-making) | — | — | n/m | −23,458.82% (below 0%: shrinking) | — | 0.00% | Compare |
| EOCN Eocene Ltd. | $2.6M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −67.74% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $2.9M | — | — | −86.31% | — | −72.84% | 87.19% | 0.00% |